Compare EFSI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSI | IVVD |
|---|---|---|
| Founded | 1881 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.1M | 212.6M |
| IPO Year | 1996 | 2021 |
| Metric | EFSI | IVVD |
|---|---|---|
| Price | $45.97 | $0.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $47.00 | $10.00 |
| AVG Volume (30 Days) | 38.2K | ★ 3.5M |
| Earning Date | 10-22-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | $3.52 | $44.85 |
| P/E Ratio | $18.39 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $31.44 | $0.53 |
| 52 Week High | $48.17 | $3.07 |
| Indicator | EFSI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 43.64 |
| Support Level | $45.07 | $0.53 |
| Resistance Level | $47.73 | $1.02 |
| Average True Range (ATR) | 1.11 | 0.05 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 40.09 | 54.34 |
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.